EARTH CITY, Mo.--(BUSINESS WIRE)--Optime Care, a nationally recognized specialty pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces the launch of Copay AdvisorSM, a first-in-class, innovative copay assistance program to proactively address challenges and unmet needs of its drug manufacturer partners. Utilizing proprietary block-chain technology as its backbone, Copay AdvisorSM minimizes potentially negative exposure with co-pay and maximizer programs for pharmaceutical manufacturers.
“This program comes at an ideal time, and we are excited to respond to the growing and often unanswered needs in the marketplace in order to support manufacturers in limiting their potential exposure relating to copay accumulator and maximizer programs,” says Tiffany Ellen Burt, President and Chief Operating Officer, Optime Care. “This is another service we can offer to new partners, as well as companies where we have deep longstanding relationships. Our goal is to continuously support our partners with these types of programs and services that streamline access to branded therapies and enhance patient outcomes.”
She points out that health equity has become a primary concern for millions of Americans who rely upon copay assistance to afford their prescribed medications.
“Optime Care is committed to serving rare patient populations who rely on copay assistance to pay for much-needed specialty drugs,” continues Burt. “In an ever-changing healthcare environment, we are committed to helping drug manufacturers reach these patients through innovative programs.”
A key differentiator from current programs, Copay AdvisorSM uses blockchain technology, an emerging technology being applied in healthcare systems to preserve and exchange patient data through hospitals, diagnostic laboratories, pharmacy firms and physicians. This digital ledger facilitates accumulation, tracking and reporting of data needed for compliance with new CMS 2023 guidelines relating to health equity.
Burt concludes, “This program was created or developed to address increased criticism from health insurers regarding typical copay assistance programs. We offer an effective alternative to existing copay programs, which are censured with complaints that they drive up costs while steering patients toward higher-priced brands. Additionally, we now can support the drug manufacturers to help ensure these programs are a win-win for all stakeholders.”
About Optime Care
Optime Care, Inc. is a nationally recognized specialty pharmacy, distribution and patient management organization offering a suite of comprehensive services tailored to maximize the therapeutic opportunities for the treatment of orphan and rare disorders. Our executive team has partnered in the launch and management of over 40 orphan products and programs while consistently implementing the best brand services for the community. Our experience with small patient populations, coupled with our strategic partnership with AscellaHealth, enhances our services and ability to serve the specialty pharmacy market. Optime Care has dual-accreditation from the Utilization Review Accreditation Commission (URAC) for compliance with specialty pharmacy and the Accreditation Commission for Health Care (ACHC) for specialty pharmacy services that demonstrate a commitment to providing quality care and services to consumers. https://www.optimecare.com/